ABI-LAB is a cutting edge incubator for research and biotechnology companies to work, grow, and thrive.
Our campus offers best-in-class infrastructure and state-of-the-art lab spaces.
Our collaborative environment offers a space for like-minded individuals to come together, exchange ideas, access shared amenities, and benefit from the guidance of experienced industry leaders, ultimately helping tenants bring their ideas to fruition.
ABI-LAB’s mission is to shorten the process of early stage and newer expanding life sciences companies by removing operational and financial obstacles.
Once we welcome a new company, we become a partner with them in their success, working tirelessly to allow their team to focus on research while we handle the rest.
We’re proud to be able to tell our tenants that they can “Move in today, start your science tomorrow.”
Our mission is to provide lab spaces that allow our companies to succeed and successfully contribute scientific innovation for the betterment of humanity. By streamlining the journey of early-stage and growing life sciences companies, we eliminate administrative, operational, and financial barriers while empowering their teams to concentrate on groundbreaking research.
We provide an environment that allows companies to thrive—which includes taking action on environmental, social, and governmental issues in order to create an inclusive and equitable environment. ABI-LAB aims to leave a more positive impact on the environment than we have taken, create a safe and positive space for tenants and employees, and maintain ethical corporate governance.
ABI-LAB started with a success story that went on to inspire a business model and then an entire company.
Dr. Raphael Nir, Chief Scientific Officer of ABI-LAB, became a founding partner of what was to become Karyopharm Therapeutics after seeing their vision being pitched on the back of a napkin. Karyopharm is now traded on NASDAQ and has two therapies approved by the FDA for multiple myeloma and lymphoma.
Emboldened by these achievements, Dr. Nir teamed up with Gary Kaufman, co-owner of ABI-LAB, to build a business model and ecosystem to help the next generation of biotech companies break barriers in their research. Since then, we have built and leased two buildings and are constructing a third, to be ready in 2024.
The 27 Strathmore building was purchased, renovated and quickly filled with 17 companies.
Eager to expand and work with more companies, Nir & Kaufman partnered up with HC Atlantic—run by David Cohen Pratt—and from there, ABI-LAB 2 was built from the ground up. The second facility quickly filled up with 25 research companies in less than two years from being constructed.
Our third facility is under construction at 3 Dean Road and anticipates opening in 2024.
ABI-LAB hopes to continue to support the next generation of biotech companies by providing more flexible and sustainable lab space.